How to get started investing in mining stocks

Everyone gets drawn to investing in mining companies for a different reason. Whether you’re a seasoned ex-mining engineer, an armchair geologist, or someone entirely new to the field, the blue sky potential that comes with investing in mining can be exciting Still, big upside comes with big risk, so investors need to be savvy. Every investment decision is an important one, and you should always do your own, extensive due diligence. However, between geology, project economics, finances, and even the jurisdictions where projects are located, there’s a lot to cover, and a lot that can be missed. Not every penny stock is a ten-bagger, and following the herd definitely isn’t a sure-fire way to success. So how do you know where to start looking? An Investor kit is a great place to start. Investor kits can save a lot of time up-front to help decide which company is right for you. They’ll clearly lay out key points on the company so that you can see the story quickly, providing a solid platform for you to move to the next steps in your research. In each investor kit, you’ll typically find:
  • The rundown on each company’s key projects
  • Their share structure and key financial information
  • What they’re doing to advance their business
Don’t waste time sifting through forums and company websites trying to piece together what the story is. Sign up for an investor kit now and start your search on the right foot. [superform_specify category_id=11740] **Note: This does not represent a solicitation to buy stock. As stated above, always do your own due diligence.**
Featured
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cronos Group Inc. resulting from allegations that Cronos may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Cronos securities you may be entitled to compensation without payment of any out of pocket fees or costs ...

-

read more Show less
Cohen Milstein Sellers & Toll PLLC today announced that its ongoing investigation has led to the filing of a class action complaint against Bristol-Myers Squibb Company and several of its senior executives and directors. The case was filed in the United States District Court for the Southern District of New York, Case No. 21-cv-10351The action was brought on behalf of all former Celgene Corporation shareholders that ...

Cohen Milstein Sellers & Toll PLLC ("Cohen Milstein") today announced that its ongoing investigation has led to the filing of a class action complaint against Bristol-Myers Squibb Company ("Bristol Myers") and several of its senior executives and directors. The case was filed in the United States District Court for the Southern District of New York, Case No. 21-cv-10351

The action was brought on behalf of all former Celgene Corporation ("Celgene") (CELG) shareholders that received Contingent Value Rights ("CVRs") in exchange for their Celgene shares pursuant to Bristol Myers' $74 billion acquisition of Celgene on November 20, 2019, and were damaged thereby, and all persons who purchased CVRs between November 20, 2019 and December 31, 2020 (the "Class Period"), and who were damaged thereby (the "Class").

read more Show less
Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in securities class action lawsuits against Bristol-Myers Squibb Company if they received Contingent Value Rights in exchange for their shares of Celgene Corporation pursuant to BMS’ acquisition of Celgene on November 20, ...

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 6, 2021 to file lead plaintiff applications in securities class action lawsuits against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE: BMY), if they received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS' acquisition of Celgene on November 20, 2019. These actions are pending in the United States District Court for the Southern District of New York.

What You May Do

read more Show less

MARKETS

Markets
TSX20633.27-128.76
TSXV897.13-13.09
DOW34580.08-59.71
S&P 5004538.43-38.67
NASD15085.47-295.85
ASX7241.20+16.00

COMMODITIES

Commodities
Gold1783.440.00
Silver22.540.00
Copper4.27-0.03
Palladium1816.010.00
Platinum936.310.00
Oil66.22-0.28
Heating Oil2.10-0.01
Natural Gas4.09+0.04